Generic Uzedy Availability
Last updated on Oct 9, 2024.
Uzedy is a brand name of risperidone, approved by the FDA in the following formulation(s):
UZEDY (risperidone - suspension, extended release;subcutaneous)
-
Manufacturer: TEVA
Approval date: April 28, 2023
Strength(s): 50MG/0.14ML (50MG/0.14ML) [RLD], 75MG/0.21ML (75MG/0.21ML) [RLD], 100MG/0.28ML (100MG/0.28ML) [RLD], 125MG/0.35ML (125MG/0.35ML) [RLD], 150MG/0.42ML (150MG/0.42ML) [RLD], 200MG/0.56ML (200MG/0.56ML) [RLD], 250MG/0.7ML (250MG/0.7ML) [RLD]
Has a generic version of Uzedy been approved?
No. There is currently no therapeutically equivalent version of Uzedy available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Uzedy. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Risperidone biodegradable implant
Patent 10,736,965
Issued: August 11, 2020
Inventor(s): Siegel Steven & Winey Karen
Assignee(s): THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIAThe present invention provides implants comprising a therapeutic drug and a polymer containing polylactic acid (PLA) and optionally polyglycolic acid (PGA). The present invention also provides methods of maintaining a therapeutic level of a drug in a subject, releasing a therapeutic drug at a substantially linear rate, and treating schizophrenia and other diseases and disorders, utilizing implants of the present invention.
Patent expiration dates:
- January 12, 2025✓
- January 12, 2025
-
Drug-containing implants and methods of use thereof
Patent 8,221,778
Issued: July 17, 2012
Inventor(s): Siegel Steven & Winey Karen
Assignee(s): The Trustees of the University of PennsylvaniaThe present invention provides implants comprising a therapeutic drug and a polymer containing polylactic acid (PLA) and optionally polyglycolic acid (PGA). The present invention also provides methods of maintaining a therapeutic level of a drug in a subject, releasing a therapeutic drug at a substantially linear rate, and treating schizophrenia and other diseases and disorders, utilizing implants of the present invention.
Patent expiration dates:
- November 12, 2027✓✓
- November 12, 2027
-
Method of maintaining therapeutic risperidone levels in a PLA:PLGA implant
Patent 8,741,327
Issued: June 3, 2014
Inventor(s): Siegel Steven & Winey Karen
Assignee(s): The Trustees of the University of PennsylvaniaThe present invention provides implants comprising a therapeutic drug and a polymer containing polylactic acid (PLA) and optionally polyglycolic acid (PGA). The present invention also provides methods of maintaining a therapeutic level of a drug in a subject, releasing a therapeutic drug at a substantially linear rate, and treating schizophrenia and other diseases and disorders, utilizing implants of the present invention.
Patent expiration dates:
- November 12, 2027✓✓
- November 12, 2027
-
Risperidone-containing PLA:PGA implants and methods of use thereof
Patent 8,802,127
Issued: August 12, 2014
Inventor(s): Siegel Steven & Winey Karen
Assignee(s): The Trustees of the University of PennsylvaniaThe present invention provides implants comprising a therapeutic drug and a polymer containing polylactic acid (PLA) and optionally polyglycolic acid (PGA). The present invention also provides methods of maintaining a therapeutic level of a drug in a subject, releasing a therapeutic drug at a substantially linear rate, and treating schizophrenia and other diseases and disorders, utilizing implants of the present invention.
Patent expiration dates:
- January 12, 2025✓
- January 12, 2025
-
Biodegradable drug delivery compositions
Patent 9,023,897
Issued: May 5, 2015
Inventor(s): Gaudriault Georges
Assignee(s): MedinCellA biodegradable drug delivery compositions comprising a triblock copolymer containing a polyester and a polyethylene glycol and a diblock copolymer containing a polyester and an end-capped polyethylene glycol, as well as a pharmaceutically active principle is disclosed.
Patent expiration dates:
- April 5, 2033✓
- April 5, 2033
-
Risperidone-containing implants and methods of use thereof
Patent 9,439,905
Issued: September 13, 2016
Inventor(s): Siegel Steven & Winey Karen
Assignee(s): THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIAThe present invention provides implants comprising a therapeutic drug and a polymer containing polylactic acid (PLA) and optionally polyglycolic acid (PGA). The present invention also provides methods of maintaining a therapeutic level of a drug in a subject, releasing a therapeutic drug at a substantially linear rate, and treating schizophrenia and other diseases and disorders, utilizing implants of the present invention.
Patent expiration dates:
- January 12, 2025✓✓
- January 12, 2025
-
Drug-containing implants and methods of use thereof
Patent 9,717,799
Issued: August 1, 2017
Inventor(s): Siegel Steven & Winey Karen
Assignee(s): THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIAThe present invention provides implants comprising a therapeutic drug and a polymer containing polylactic acid (PLA) and optionally polyglycolic acid (PGA). The present invention also provides methods of maintaining a therapeutic level of a drug in a subject, releasing a therapeutic drug at a substantially linear rate, and treating schizophrenia and other diseases and disorders, utilizing implants of the present invention.
Patent expiration dates:
- January 12, 2025✓
- January 12, 2025
-
Drug-containing PLA implants and methods of use thereof
Patent 9,895,447
Issued: February 20, 2018
Inventor(s): Siegel Steven & Winey Karen
Assignee(s): THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIAThe present invention provides implants comprising a therapeutic drug and a polymer containing polylactic acid (PLA) and optionally polyglycolic acid (PGA). The present invention also provides methods of maintaining a therapeutic level of a drug in a subject, releasing a therapeutic drug at a substantially linear rate, and treating schizophrenia and other diseases and disorders, utilizing implants of the present invention.
Patent expiration dates:
- January 12, 2025✓
- January 12, 2025
-
Drug-containing implants and methods of use thereof
Patent 9,925,268
Issued: March 27, 2018
Inventor(s): Siegel Steven & Winey Karen
Assignee(s): THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIAThe present invention provides implants comprising a therapeutic drug and a polymer containing polylactic acid (PLA) and optionally polyglycolic acid (PGA). The present invention also provides methods of maintaining a therapeutic level of a drug in a subject, releasing a therapeutic drug at a substantially linear rate, and treating schizophrenia and other diseases and disorders, utilizing implants of the present invention.
Patent expiration dates:
- January 12, 2025✓
- January 12, 2025
Related exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
Exclusivity expiration dates:
- April 28, 2026 - NEW PRODUCT
More about Uzedy (risperidone)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: atypical antipsychotics
- Breastfeeding
- En español
Patient resources
Other brands
Risperdal, Risperdal Consta, Perseris, Risvan, ... +2 more
Professional resources
Other brands
Risperdal, Risperdal Consta, Perseris, Rykindo
Related treatment guides
Glossary
Term | Definition |
---|---|
Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.